Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Cameroon

Cameroon

The Other Vaccines market in Cameroon is anticipated to achieve a revenue of US$5.96m in 2024.
It is projected to exhibit a steady annual growth rate (CAGR 2024-2029) of 10.28%, leading to a market volume of US$9.72m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$24,730.00m in 2024.
Cameroon is experiencing an increased demand for other vaccines due to the country's efforts in expanding its immunization programs.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Cameroon has been steadily developing over the past few years due to various factors.

Customer preferences: Cameroon has a high demand for vaccines due to its high disease burden, including malaria, yellow fever, and meningitis. In addition, the government has been actively promoting vaccination programs, which has led to an increase in demand for other vaccines.

Trends in the market: One of the major trends in the Other Vaccines market in Cameroon is the increasing demand for pneumococcal vaccines. This is due to the high incidence of pneumococcal disease in the country, which has led to increased awareness and demand for the vaccine. Another trend is the increasing availability of vaccines in rural areas, which has been made possible by the government's efforts to expand healthcare services in these areas.

Local special circumstances: One of the unique circumstances in Cameroon is the presence of a large number of refugees and internally displaced persons due to conflicts in neighboring countries. This has led to an increased demand for vaccines, as these populations are often more susceptible to disease due to poor living conditions.

Underlying macroeconomic factors: Cameroon's economy has been growing steadily over the past few years, which has led to an increase in disposable income and healthcare spending. In addition, the government has been investing heavily in the healthcare sector, which has led to an increase in the availability of vaccines. However, there are still challenges in terms of affordability and access to vaccines, particularly in rural areas.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.